Tafasitamab plus lenalidomide added to R-CHOP cut the risk of disease progression or death by 25% versus R-CHOP alone in the phase 3 frontMIND trial, with results presented at ASCO 2026. Among patients with centrally confirmed diagnosis, the PFS improvement hit 32%.
The number that matters for market positioning: Monjuvi’s 25% PFS hazard ratio in all-comers sits just below Polivy-R-CHP’s 27%, which won FDA approval in first-line DLBCL in 2023. At three years, 67.3% of Monjuvi-arm patients were alive and progression-free, versus 60.7% on R-CHOP.
Headline-to-headline, that looks like a tie. But Monjuvi’s case for differentiation runs through a subgroup Polivy never cracked: the germinal center B-cell-like (GCB) subtype, where Polivy-R-CHP showed no benefit in the Polarix trial. If Incyte’s FDA filing holds together, it could claim a population Roche can’t.
The regimen’s cost is real: seven drugs versus Polivy’s five, and grade 3-or-above adverse events in 86.7% of the Monjuvi arm versus 76.1% on R-CHOP. Treatment discontinuations were nearly identical at 5.2% vs 5.4%, which Incyte will use to argue the safety delta is manageable.
The OS read is still pending. A preliminary 15% improvement in overall survival didn’t reach statistical significance at this interim; three-year OS was 81.1% versus 77.8%. The FDA had reservations about Polivy on the same grounds. Final analysis is expected in about two years.
Incyte doesn’t have a follow-up DLBCL program in mid-to-late development. If T-cell engagers from AbbVie/Genmab and Roche read out well in first-line while Monjuvi is still waiting on OS data, the window to establish as standard of care narrows fast.
Monjuvi’s accelerated approval in second-line DLBCL came in 2020 on single-arm data. Worth auditing your formulary assumptions before Incyte files the sNDA.
Rebecca Lauren